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Abstract − The EVA descriptor is derived from fundamental IR- and Raman range molecular 
vibrational frequencies.  EVA is sensitive to 3D structure but has an advantage over field-based 
3D-QSAR methods inasmuch as it is invariant to both translation and rotation of the structures 
concerned and thus structural superposition is not required.  The latter property and the 
demonstration of the effectiveness of the descriptor for QSAR means that EVA has been the 
subject of a great deal of interest from the modelling community.  This review describes the 
derivation of the descriptor, details its main parameters and how to apply them, and provides an 
overview of the validation that has been done with the descriptor.  A recent enhancement to the 
technique is described which involves the localised adjustment of variance in such a way that 
enhanced internal and external predictivity may be obtained.  Despite the statistical quality of 
EVA QSAR models the main draw-back to the descriptor at present is the difficulty associated 
with back-tracking from a PLS model to an EVA pharmacophore.  Brief comment is made on the 
use of the EVA descriptor for diversity studies and the similarity searching of chemical structure 
databases. 
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1.  Introduction 
The advent in the late 1980's of three-dimensional QSAR [1,2] based upon the comparison of 
steric, electrostatic and subsequently hydrophobic [3,4] molecular “fields” addressed one of the 
key deficiencies of the otherwise extremely successful classical QSAR techniques [5,6].  The 
CoMFA (Comparative Molecular Field Analysis) [1] and related methods [7,8] have since proved 
to be extremely popular and effective complements to classical QSAR [6].  However, one of the 
main difficulties associated with (and potential benefits of) field-based techniques is that of 
aligning the structures concerned [9,10] where the term alignment covers both conformation 
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selection and the superposition of the chosen conformers in such a way as to provide both 
internally descriptive and externally predictive regression models of high quality.  There has thus 
been much interest in either tackling the alignment issue head-on [9, 11-15] or in seeking 
alternative molecular descriptors that are both sensitive to 3D-structure but that do not require 
structural superposition [11,13,14].  EVA [18-23] is one example of such a descriptor, based as it 
is upon molecular vibrations the characteristics of which are, in the absence of an external 
modifying influence such as a receptor, invariant to rotation and translation of the structures 
concerned.  However, whilst EVA removes the need for superposition the method is sensitive to 
3D structure although not to such an extent as a “true” 3D method such as CoMFA.  This reduced 
sensitivity is a consequence of the use of a Gaussian smearing function to develop the descriptor 
(as described below) and as a result EVA might be described as a “2½D” descriptor.  
Nonetheless, it has been demonstrated that it is beneficial to “match” conformations across a 
dataset where possible rather than using randomly or arbitrarily selected 3D structures [21]. 
2.   Calculation of the EVA descriptor 
EVA, and its associated data standardisation technique described below, was originally 
developed by workers at Shell Research Limited [18, 19].  The rationale behind the use of such 
information as a molecular descriptor was “that a significant amount of information pertaining to 
molecular properties, in particular biological activity, might be contained within the molecular 
vibration wave-function, of which the vibrational spectrum is a fingerprint” [19].  It is also the 
case that there is a close, albeit complex, relationship between molecular 3D structure and the 
corresponding IR spectrum, a characteristic that has made IR spectroscopy an extremely powerful 
tool for determining and identifying chemical structures.  
The descriptor is derived from IR- and Raman-range molecular vibrations typically obtained 
through the application of a classical normal co-ordinate analysis (NCA) to an appropriately 
energy minimised structure.  For a compound with N atoms there are 3N−6 (or 3N−5 for a linear 
structure such as acetylene) normal modes of vibration, each of which has a characteristic 
frequency of vibration; the latter is more usually expressed (in cm-1) as a vibration wave number 
(vwn).  The EigenVAlues from the NCA correspond to the vwns.  Once determined, from 
whatever source, the set of vwns for a given structure is projected onto a linear bounded 
frequency scale (BFS) typically covering a range from 1 to 4,000 cm-1.  The use of this range 
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means that all fundamental vibrational normal modes are included in the analysis – should a vwn 
exceed 4,000 cm-1 then either the BFS can be extended or all vwns from all molecules can be 
scaled according to scale factors such as those described by Scott and Radom [24].  Next a 
Gaussian kernel of fixed standard deviation (σ) is placed over each and every frequency value.  
The BFS is then sampled at fixed increments of L cm-1 and the value of the resulting EVA 
descriptor, EVAx, at each sample point, x, is the sum of the amplitudes of the overlaid kernels at 
that point: 
 
22/2)fx(e
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−−∑−==         (1) 
where fi is the ith normal mode frequency of the compound concerned.  This procedure is repeated 
for each dataset compound and then combined to provide a matrix with M rows (compounds) and 
4,000/L (columns) descriptor variables.  Typically a descriptor set has been derived using a σ of 
10 cm-1 and an L of 5 cm-1 giving 800 descriptor variables [19, 20].  Thus, for a QSAR dataset of 
typical size the number of variables is very much larger than M and a method such as Partial least 
squares to Latent Structures (PLS) in conjunction with crossvalidation [25] is required to provide 
a robust regression analysis.   
It is important to note that the purpose of the EVA smoothing procedure is not to simulate an 
experimental IR spectrum (transition dipole data is discarded and overtones etc. are not 
considered) but rather it is to apply a smearing function such that vibrations at slightly different 
frequencies in different compounds can be compared with one another.  As such the results 
obtained with EVA QSAR are usually dependent upon the chosen kernel width (σ) [20-22] since 
this parameter determines whether or not, and the extent to which, proximal kernels overlap.  A 
general approach for choosing an appropriate Gaussian σ is described below together with a 
detailed explanation of how the sampling resolution (determined by L) should be selected.  It 
should be noted that the use of a fixed Gaussian standard deviation (kernel height, width and 
shape) means that each frequency (i.e., each part of the spectrum) is equally weighted prior to 
regression analysis. 
Finally, the smearing procedure described can be applied using functions other than the 
Gaussian such as, for example, a Lorentzian, triangular or box function; in-house, and rather ad 
hoc, experience suggests that these shapes provide no advantage in terms of QSAR statistical 
scores.  Alternatively, the smearing technique has been applied to other non-standard spectral and 
non-spectral molecular properties with some success; details are provided below. 
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3.  Selection of parameter values 
As noted above the purpose of applying the Gaussian kernels to the vwns is to smear them out 
such that vibrations at slightly different frequencies in different compounds can be compared to 
one another.  The univariate variance of each EVA variable thus depends upon the chosen 
Gaussian σ and the relative disposition of the vwns both inter- and intra-structurally.  Given that 
the descriptor variance depends upon these factors it follows that any variance-based method such 
as PLS is sensitive to the chosen Gaussian σ.  It is indeed the case that optimal σ (as judged by 
the resulting PLS scores) can be identified for particular data sets [20, 21] although the sensitivity 
to σ is a data set-dependent feature.  The much discussed “benchmark” steroid data set [26], for 
example, is particularly sensitive to σ (as demonstrated in Figure 1) [21].  In this example, 
models were obtained for a range of σ from 1 to 25 cm-1 and LOO crossvalidation, fitted 
modelling and prediction performed for each descriptor set; PLS model dimensionality was 
chosen on the basis of the first SEcv-minimum.  It is clear that the best internally predictive 
models (judged by q2) are obtained where σ = 3-4 cm-1 and, gratifyingly, test set (i.e., external) 
predictivity is also clearly optimal for this σ.  For a set of melatonin receptor ligands [22, 27] 
there is no such clear optimal σ for q2 (Figure 2); any value of σ in the range 1 to 10 cm-1 gives a 
q2 of ~0.47 while the q2 drops off where σ > ~ 10 cm-1.  The corresponding test set predictivity on 
the other hand shows an optimum at around 4 cm-1 but this peak is not nearly so pronounced as it 
is for the steroid set.  The overall conclusion from a wide range of analyses [21] was that a default 
σ of 10cm-1 is a useful starting point but that it is definitely worth exploring models derived using 
alternative σ values. 
Care also needs to be taken when selecting an appropriate value of L, the sampling increment 
for the BFS.  For both EVA and CoMFA the descriptors used for regression are obtained by a 
sampling of the descriptor space for each molecule, respectively the Gaussian smeared vwns and 
the steric/electrostatic/hydrophobic distance potential functions (loosely referred to as “fields”).  
With CoMFA the properties of a particular molecular descriptor sample are determined by the 
grid resolution and, at coarse resolutions (see below), by the relationship of the grid-sample 
points to the molecules.  With EVA such properties are determined by the sampling interval (L) 
and, at coarse resolutions, by the "reading frame" (determined by S, the point at which sampling 
of the BFS is initiated – default 1 cm-1).  Thus, a key issue in extracting these descriptors is the 
resolution required to obtain a sample with properties that reflect as closely as possible those of 
the population as a whole.  Theoretically, this can be done by using an infinitely small sampling 
resolution.  Of course this is not possible and in practice the resolution chosen is a compromise 
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between computational resource/time available for analysis and the stability of the derived PLS 
models.  However, it is possible to identify a sufficient resolution for both EVA and CoMFA 
modelling.  In the latter case this amounts to choosing a grid-resolution for which the resultant 
PLS scores are invariant (at a given significance level) to the aggregate reorientation/translation 
of the aligned structures relative to the bounding 3D-grid.  Where the grid-resolution is 
insufficient, crossvalidation q2 scores can vary significantly [28] and, as recent studies have 
shown [21,22], the test set predictivity can exhibit even greater variance.  Only once a sufficiently 
descriptive grid resolution has been established (typically, ≤ 1 Å [22]) does it make sense to apply 
rational or systematic variable selection techniques to try and obtain simplified models with 
enhanced predictivity.   
With EVA an entirely analogous situation exists – the sampling interval (L) (the resolution) 
must be such that the sample of descriptor space obtained (prior to any systematic variable 
selection) is truly representative of the underlying population.  Thus, for a given choice of 
Gaussian σ, critical values of L (denoted σCritL ) can be estimated based upon examination of the 
PLS scores obtained over a range of L.  The results of applying this procedure at various Gaussian 
σ have been described previously [20, 29] and a general rule-of-thumb is to choose  L so that it is 
< 2σ.  Further examples of such evaluations are given in Figures 3 and 4 using a set of phenolic 
compounds with log10 (1/MIC) for the oral bacteria P. gingivalis [30,31].  There is an additional 
factor to be considered here in as much as the “reading frame”, determined by the point (S) 
chosen to initiate sampling of the BFS, provides an alternative source of descriptor variation.  
Thus, Figures 3-4 respectively illustrate the range of LOO CV q2 or test pr-r2 scores obtained 
where the Gaussian σ = 1 cm-1 and the sampling interval L is varied from 0.2 to 6 cm-1 in 0.2 cm-1 
increments; each line represents results obtained where S has a value taken from the range 1.0 
(the default) to 1.9 cm-1 in 0.1 cm-1 increments.  It is clear that where L < 2 cm-1 the PLS scores 
are stable but that once L > ~ 2cm-1 this stability is lost, indicating that the signal-to-noise ratio in 
the descriptors is varying.  Similar analyses can be done for alternative Gaussian kernel widths 
from which the rule-of-thumb noted above has been established. 
In general terms it is useful to keep L as large as possible so as to minimise computational and 
storage requirements which may be important where a small σ term (and hence L value) is 
utilised or where a very large dataset is to be modelled.  All models reported here are those for 
which the relevant L « σCritL  and where S is the default 1 cm
-1. 
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4.  The effectiveness of the EVA descriptor 
EVA was originally developed as a descriptor for QSAR [18, 19] and it has been shown to 
perform well with a wide range of datasets [19-21]; Table 1 lists a summary of EVA QSAR 
modelling statistics with data from various sources taken both from the literature and unpublished 
in-house analyses.  Many of these analyses were done without a test set, and for these internal 
validation statistics only are available.  A number of the reported QSARs have been further 
validated both with test sets and using data scrambling techniques [21, 22].  This wide range of 
successful analyses attests to the general usefulness of EVA as a QSAR descriptor.   
In terms of similarity/dissimilarity-based diversity analyses the Tripos neighbourhood 
behaviour criterion [32] provides a useful base-line from which to proceed.  In essence a 
descriptor exhibits neighbourhood behaviour where small differences in a descriptor value tend to 
produce only a small difference in biological activity; i.e., high similarity in descriptor space 
implies similar biological activity.  The converse, that dissimilar molecules will have dissimilar 
biological activities, need not be and, fortunately for diversity-based lead discovery is not, a 
requirement.  Put another way, similarity in descriptor space is a sufficient, but not necessary, 
condition for similar biological activity.  The EVA descriptor has indeed been shown to exhibit 
neighbourhood behaviour [33] thus providing support for its use in diversity analysis/compound 
selection protocols. 
EVA has also been evaluated for use in similarity searching of structure databases, using 
simulated property-prediction methods.  Two evaluations have been performed.  The first made 
use of the Pomona Starlist database with high-quality experimentally determined log P values as 
the property to be predicted [23].  Performance here was as only as good as conventional 2D-bit-
string descriptors, specifically those in the UNITY chemical information management package 
[34].  However, detailed examination of the nearest-neighbour “hits” indicated that EVA tended 
to return quite different structures to those obtained with the 2D descriptor, suggesting that EVA-
based similarity searching may be useful as an “ideas generator” for the browsing chemist.  A 
second, unpublished study has been made using subsets of the World Drugs Index. In these 
analyses similarity searching performance was assessed according to how many compounds of 
the same activity class were found in nearest-neighbour lists for various selected targets. The 
results were compared to those obtained using UNITY 2D bit-strings, and it was again found that 
EVA provides similar performance to bit-string-based searching but tend to return different sets 
of nearest-neighbours. 
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The main obstacle to the utilisation of EVA descriptors in similarity and diversity-studies is 
the overhead required to calculate the vwns for which a geometry optimisation step is a pre-
requisite; even with a molecular mechanics approach such as MM3 [35] the time required is at 
least an order of magnitude higher than that needed for 2D fragment bit-string descriptors, for 
example.  The extent to which geometry optimisation can be relaxed, and the time required to 
determine vwns thus reduced, without significantly affecting descriptor performance has yet to be 
assessed.  
5.  A modification to the EVA methodology - EVA_GA 
In “classical” EVA described above the Gaussian kernels have a uniform fixed σ (i.e., equal 
width, height and shape) for all frequencies in all compounds being analysed.  This is important 
because it means that each frequency (i.e., each part of the spectrum) is equally weighted prior to 
regression.  In the EVA_GA method [22] the kernel standard deviation (σ) is permitted to have 
localised values at different regions on the BFS.  This approach permits the determination of an 
optimal or near-optimal overlap of kernels across the spectrum, where the quality of this overlap 
is judged by the scores from subsequent PLS regression with the derived descriptor matrix.  Equal 
weighting of frequencies prior to analysis is ensured by scaling the kernels such that they have 
unit maximum amplitude; the main difference between the kernels is thus their width and to a 
lesser extent shape. 
For EVA_GA the BFS is divided up into NBINS bins of equal size and a localised σ 
associated with each bin.  A frequency value falling within a bin range is thus expanded using the 
associated local σ.  A GA is used to drive the search for optimal combinations of localised σ, 
with the GA chromosome consisting of a vector of NBINS σ values.  A typical value of NBINS 
is 100 giving a bin width of 40 cm-1.  PLS LOO or LNO CV regression scores (i.e., q2) have been 
used as the fitness function to be optimised by the GA and the final solution(s) validated using 
previously unseen, test sets of compounds.  Results with EVA_GA have thus far been extremely 
promising with substantial improvements in both q2 and test set predictive-r2 (pr2) scores with a 
set of melatonin ligands (Table 2) and a set of phenolic compounds with oral bacteria inhibition 
data; when applied to the benchmark steroid dataset (not shown) an improvement in q2  but no 
change in pr2 was obtained. 
Whilst these results are very promising it has been found that a great deal of care is required to 
prevent training set overfit, even where LNO CV q2 is used as the GA fitness score.  The GA 
maybe also be applied as a variable selection/deletion tool wherein a variable can be deselected 
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when a localised σ of zero is permitted.  Such variable selection provides simplified models 
which in turn may provide greater opportunity to back-track effectively to structure from an EVA 
QSAR.  Model interpretation is one of the most appealing features of the CoMFA method while 
at present such ready back-transformation is not available within EVA.  We are hence also 
investigating the use of alternative techniques such as continuum regression [36] and various 
variable selection procedures [37-39] that in combination may provide better or more appropriate 
reduced-variable models. 
6.  Related descriptors 
As indicated previously [19,20,40] the Gaussian smearing methodology is not restricted to 
vwns but can in fact be applied to any suitable non-standard property.  The method has since been 
applied to other spectral properties [41] − the so-called Comparative Spectra Analysis (CoSA) − 
including experimentally determined 1H NMR, Mass and IR spectra as well as simulated IR and 
13C NMR data.  The various descriptors were tested using a single set of 45 progestagens, both 
with all compounds as a training set and where the compounds were divided into a training and 
test set.  With the exception of experimental IR descriptors, results with individual spectral 
descriptors were generally better than analogous CoMFA analyses; combining the descriptors, 
including the molecular fields, in various ways tended to improve the PLS scores obtained.   
The Gaussian smearing technique has also been applied to molecular orbital (MO) energies 
[42].  The MO energies were obtained semi-empirically and are thus the Electronic EigenVAlues 
(EEVA).  EEVA has been tested on seventeen data sets with LOO crossvalidated q2 > 0.4 in all 
cases except two and some very high q2 scores (up to 0.94) in many cases; external test set 
predictivity was not considered here.  In the authors’ opinion some of these results are over-
optimistic in as much as models are reported with large numbers of PLS LVs relative to the 
number of data-points (compounds).  Nonetheless, there are sufficient numbers of significant 
results presented to suggest that EEVA is a promising descriptor.  Furthermore, an in-house 
EEVA analysis using the aforementioned steroid dataset [1,26] has however provided models 
with both good internal and external predictivity (Gaussian σ = 9 eV, q2 = 0.75 (4); r2 = 0.97; pr-
r2 = 0.59).  
7.  Conclusion 
EVA has proved to be an effective and robust descriptor for use in QSAR studies as evidenced 
by the large number of successful analyses documented herein.  EVA has been found to perform 
as well as CoMFA overall but with the advantage that structural superposition is not required.  
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EVA’s main limitation is that PLS regression models are very difficult to interpret in terms of 
(contra)-indicated molecular features.  However, efforts are underway to simplify regression 
models through variable selection techniques such that back-tracking from a model may be 
facilitated.  The descriptor has also been validated for use in diversity/compound selection 
protocols through the demonstration of its neighbourhood properties and through nearest-
neighbour based simulated property-prediction studies. 
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Dataset1 n2
 
Biological End-point / Property 
        Best                σ = 10 cm-1
   q2 (ONL) σ       q2 (ONL) 
Test Set pr-r2
Best σ  / σ = 10 cm-1
β-Carboline [20] 41 benzodiazepine receptor inverse 
agonists and antagonists (log 
IC50) 
0.66 (7) 22 0.50 (6) -  - 
BCDEF [19] 135 + 68 Experimental log P -  -  0.68 -  0.65 
Biphenyls  (BIP) [20] NS 
         AS 
14 Ah (Dioxin) Receptor Binding 
Affinity (pEC50) 
0.14 (3) 7  ≤ 0 
0.45 (3) 16 0.28 (2) 
-  - 
-  - 
Cain/Cometto-Muniz  52 
44 
Odour thresholds (ODT)3
Log( 1 / ODT) 
0.57 (5) 25 0.54 (5) 
0.71 (7) 15 0.62 (5) 
-  - 
-  - 
Dibenzo-p-dioxins (DPD) [20] 25 Ah (Dioxin) Receptor Binding 
Affinity (pEC50) 
0.70 (2) 18-40 0.65 (2) -  - 
Dibenzofurans (DBF) [20] 39 Ah (Dioxin) Receptor Binding 
Affinity (pEC50) 
0.74 (4) 7-9 0.73 (4) -  - 
DPD + BIP + DBF combined 
[20] 
78 Ah (Dioxin) Receptor Binding 
Affinity (pEC50) 
0.64 (3) 14-21 0.62 (3) -  - 
Endothelins  Abbott [43] 55 ETA receptor (1/logIC50) 0.49 (2) 50 0.58 (3) -  - 
 BMS [44] 36 ETA receptor (1/logIC50) 0.54 (3) 1  0.71 (5) -  - 
Melatonin Receptor Ligands 
[22] 
44 + 9 pKi for chicken brain melatonin 
receptors 
0.46 (2) 10 as best 0.66/0.814 as best 
Muscarinics  [20] 39 muscarinic agonists (pD2) 0.53 (4) 10 as best -  - 
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Nitromethylene heterocycles 
[20] 
17 1/log LC50 values for the pea 
aphid 
0.66 (3) 4  0.49 (3) -  - 
Oxadiazoles  [20] NSg 
                    AS 
23 toxicity index (TI) for red spider 
mite eggs (1/log TI) 
≤ 0  -  ≤ 0 
≤ 0  -  ≤ 0 
-  - 
-  - 
Phenols [30,31] P. gingivalis5 62 + 62 Log( 1/MIC ) 0.81 (3) 10 as best 
0.69 (3) 10 as best 
0.75  as best 
0.83  as best 
  Str. Sobrinus5 56 + 55 Log( 1/MIC ) 0.85 (3) 10 as best 
0.83 (6) 10 as best 
0.78  as best 
0.89  as best 
  S. artemidis5 55 + 55 Log( 1/MIC ) 0.68 (3) 10 as best 
0.74 (6) 10 as best 
0.61  as best 
0.69  as best 
Piperidines [20] 137 1/log IC50 for U. Maydis 0.78 (3) 2-4 0.76 (4) -  - 
Steroids  (TBG) [20] 21 testosterone- and corticosterone-
binding globulin (TBG and 
CBG) binding affinity (log [K]).
0.70 (4) 8-11 0.70 (4) -  - 
Steroids  (CBG) [20] 21 + 10 As above 0.75 (1) 3  0.70 (2) -  - 
Steroids  (CBG) [21] 21 + 10 As above 0.80 (2)  3/4 0.73 (2) 0.69  0.59 
Steroids (CBG)  Design_1 [22] 11 + 20 As above 0.55 (1)6 4  0.55 (2)6 0.51  0.34 
    Design_2 
[22] 
10 + 18 As above 0.69 (2) 4  0.63 (2) 0.69  0.63 
Sulphonamides [20] 100 log 1/IC50 for acetolactate 
synthase inhibition 
0.55 (3) 2  0.56 (7) 
0.57 (7) 7- 8 
-  - 
-  - 
Tropanes [20] 13 cocaine binding site (1/log IC50) 0.68 (3) 65 (+) 0.49 (2) 
0.55 (3) 13  
-  - 
-  - 
 13
1 Citations refer either to papers where the relevant EVA QSAR analyses are described (within which further references are given) or, where such is not available, the original 
literature reference is given. 
2 n – number of training set compounds (+ number of test set compounds where available). 
3 Minimum vapour concentrations that human subjects can detect in ppm. 
4 Test set pr-r2 excluding two outliers. 
5 These datasets were split into two equal-sized groups and models developed for each group were used to predict the activities of the compounds in the other group. 
6 The model based on Gaussian σ of 4 cm-1 has identical q2 to that where σ = 10 cm-1 but the former is preferred since it uses one rather than 2 LVs; test set prediction is 
better with the simpler model. 
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Table 2:  Some EVA_GA results: melatonin receptor ligands [22] and bacteria inhibiting phenolic compounds: see Table I for equivalent “classical” EVA 
results and further details. 
  Training Set Test Set 
Dataset n LOO q2 ONL RAND_PERM
1
p for q2
r2 Predictive-r
2
Melatonin 44 0.65 3 3.0 × 10-5 0.90 0.72 / 0.89 
Phenols / P. 
gingivalis 
62 0.89 3 3.2 × 10-7 0.93 0.77 
Phenols / S. 
sobrinus 
56 0.90 3/4 6.7 × 10-6 0.97 0.79 
Phenols / Str. 
Artemidis 
55 0.77 2 1.3 × 10-8 0.95 0.64 
 
 
1 RAND_PERM: training set random permutation (Y scrambling) tests: p gives an estimate of the probability that the observed model may have occurred by 
chance. 
2 Test set pr-r2 excluding two outliers. 
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Figure 1: Steroid dataset: PLS q2 or test set pr-r2 vs. Gaussian σ (see main text for 
further details).  
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Figure 2: Melatonin receptor ligands: PLS q2 or test set pr-r2 vs. Gaussian σ (see main text for further details). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: P. ors derived where 
the BFS is sampled starting at S cm
 gingivalis phenolic inhibitors: Training set LOO CV q2 vs. sampling increment (L) where Gaussian σ = 1.0 cm-1. Each line represents descript
-1.  The q2 is stable only where L < ~2σ. 
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Figure 4: P. gingivalis phenolic inhibitors: Test set pr-r2 vs. sampling increment (L) where Gaussian σ = 1.0 cm-1. Each line represents descriptors derived where the BFS is 
sampled starting at S cm-1.  The pr-r2 is stable only where L < 2σ. 
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